Search

Your search keyword '"Adalimumab -- Prices and rates"' showing total 3 results
Start Over Descriptor "Adalimumab -- Prices and rates" Topic business
3 results on '"Adalimumab -- Prices and rates"'

1. Adalimumab Biosimilars Insight by DelveInsight

Subjects
Psoriasis -- Forecasts and trends -- Reports, Rheumatoid factor -- Reports -- Forecasts and trends, Arthritis -- Reports -- Forecasts and trends, Adalimumab -- Prices and rates, Tumor necrosis factor -- Forecasts and trends -- Reports, Market trend/market analysis, Company pricing policy, Business, Business, international, Humira (Medication) -- Prices and rates
Abstract

M2 PRESSWIRE-November 30, 2021-: Adalimumab Biosimilars Insight by DelveInsight (C)1994-2021 M2 COMMUNICATIONS RDATE:30112021 DelveInsight's, 'Adalimumab Biosimilar Insight' report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs [...]

Published
2021

2. Adalimumab Biosimilars Insight, 2020 | DelveInsight Report Analysis

Subjects
Pfizer Inc. -- Forecasts and trends, Psoriasis -- Forecasts and trends -- Reports, Rheumatoid factor -- Reports -- Forecasts and trends, Homeopathy -- Materia medica and therapeutics, Therapeutics -- Prices and rates, Arthritis -- Reports -- Forecasts and trends, Adalimumab -- Prices and rates, Pharmaceutical industry -- Forecasts and trends, Market trend/market analysis, Company pricing policy, Business, Business, international, Humira (Medication) -- Prices and rates
Abstract

M2 PRESSWIRE-March 5, 2021-: Adalimumab Biosimilars Insight, 2020 | DelveInsight Report Analysis (C)1994-2021 M2 COMMUNICATIONS RDATE:04032021 DelveInsight's, 'Adalimumab Biosimilar Insight, 2020,' report provides comprehensive insights about 35+ companies and 45+ [...]

Published
2021

3. Biden can lower drug prices without Congress doing anything

Subjects
Diabetes therapy -- Prices and rates, Drugs -- Prescribing, Adalimumab -- Prices and rates, Pharmaceutical industry -- Prices and rates -- Political aspects -- Political activity, Company pricing policy, Business, Computers and office automation industries, Telecommunications industry
Abstract

Byline: Doni Bloomfield;Aaron S. Kesselheim Though President Trump spent the past four years railing against drug manufacturers, his administration had little success in curbing pharmaceutical prices. In 2019 alone, Americans [...]

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results